Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

October 12, 2017: By Jon Swedien

AlconAlcon announced Sept. 29 that its AcrySof intraocular lenses (IOLs) have been implanted more than 100 million times.

In celebration, Alcon launched its “100 Million Moments Made” campaign, which includes resources designed to showcase the accomplishment in markets around the globe, the Fort Worth, Texas, company said.

The first recorded implantation of an AcrySof IOL was in the UK in 1990. Since then, the platform has grown to include solutions for correcting astigmatism (AcrySof IQ Toric) and presbyopia (AcrySof IQ ReSTOR and PanOptix), Alcon said.

The AcrySof family of IOLs includes brands available in approximately 120 markets: AcrySof IQ, AcrySof IQ Toric, AcrySof IQ ReSTOR, AcrySof IQ ReSTOR Toric, AcrySof IQ PanOptix, and AcrySof IQ PanOptix Toric.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023